Literature DB >> 15161662

Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression.

Isabelle Bolon1, Hong-Ming Zhou, Yves Charron, Annelise Wohlwend, Jean-Dominique Vassalli.   

Abstract

Increased expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) is associated with different pathological conditions. Both uPAR-mediated signaling and plasmin-catalyzed extracellular proteolysis may contribute to pathogenesis. To evaluate the involvement of plasminogen in such circumstances, we have taken advantage of transgenic mouse models in which overexpression of uPA and/or uPAR in enamel epithelium, basal epidermis, and hair follicles leads to a pathological phenotype; uPA transgenic mice have chalky-white incisors and, when uPAR is co-expressed, develop extensive alopecia, epidermal thickening, and subepidermal blisters. We report here that when these transgenic mice were backcrossed into a plasminogen-deficient (Plg-/-) background, the dental and skin phenotypes appeared completely normal. Heterozygous Plg+/- transgenic mice exhibited a haplo-insufficiency, with an intermediate or normal phenotype. These results do not argue in favor of a role for uPAR-mediated signaling in our experimental model; rather, they demonstrate an essential, dose-dependent, requirement for plasminogen in uPA-mediated tissue alterations. They also support the hypothesis that plasminogen could play a part in certain skin diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161662      PMCID: PMC1615761          DOI: 10.1016/S0002-9440(10)63786-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

Review 1.  The plasminogen activator system: biology and regulation.

Authors:  J P Irigoyen; P Muñoz-Cánoves; L Montero; M Koziczak; Y Nagamine
Journal:  Cell Mol Life Sci       Date:  1999-10-01       Impact factor: 9.261

Review 2.  uPAR: a versatile signalling orchestrator.

Authors:  Francesco Blasi; Peter Carmeliet
Journal:  Nat Rev Mol Cell Biol       Date:  2002-12       Impact factor: 94.444

3.  Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.

Authors:  Theda Schuh; Robert Besch; Evelyn Braungart; Michael J Flaig; Kathrin Douwes; Christian A Sander; Viktor Magdolen; Christopher Probst; Katja Wosikowski; Klaus Degitz
Journal:  Biol Chem       Date:  2003-02       Impact factor: 3.915

4.  Phase separation of integral membrane proteins in Triton X-114 solution.

Authors:  C Bordier
Journal:  J Biol Chem       Date:  1981-02-25       Impact factor: 5.157

5.  Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.

Authors:  H M Zhou; A Nichols; P Meda; J D Vassalli
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

6.  Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.

Authors:  M G Mahoney; Z H Wang; J R Stanley
Journal:  J Invest Dermatol       Date:  1999-07       Impact factor: 8.551

7.  Plasminogen is present in the basal layer of the epidermis.

Authors:  R R Isseroff; D B Rifkin
Journal:  J Invest Dermatol       Date:  1983-04       Impact factor: 8.551

8.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

9.  Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages.

Authors:  J D Vassalli; J M Dayer; A Wohlwend; D Belin
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

10.  Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.

Authors:  K Hashimoto; K M Shafran; P S Webber; G S Lazarus; K H Singer
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more
  6 in total

1.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Authors:  Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Journal:  EMBO J       Date:  2005-04-07       Impact factor: 11.598

2.  Urokinase-type plasminogen activator mRNA is expressed in normal developing teeth and leads to abnormal incisor enamel in alpha MUPA transgenic mice.

Authors:  Ruth Miskin; Tamar Masos; Zipi Shoham; Lisa Williams-Simons
Journal:  Transgenic Res       Date:  2006-04       Impact factor: 2.788

3.  Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.

Authors:  Lin Lin; Henrik Gårdsvoll; Qing Huai; Mingdong Huang; Michael Ploug
Journal:  J Biol Chem       Date:  2010-02-04       Impact factor: 5.157

4.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Virote Sriuranpong; Vivien Redeye; Tricia Murdock; Beth Burke; Boye S Nielsen; J Silvio Gutkind; Thomas H Bugge
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

5.  Genome resequencing and bioinformatic analysis of SNP containing candidate genes in the autoimmune vitiligo Smyth line chicken model.

Authors:  Hyeon-Min Jang; Gisela F Erf; Kaylee C Rowland; Byung-Whi Kong
Journal:  BMC Genomics       Date:  2014-08-23       Impact factor: 3.969

Review 6.  Extracellular proteolysis in transgenic mouse models of breast cancer.

Authors:  Kasper Almholt; Kirsty Anne Green; Anna Juncker-Jensen; Boye Schnack Nielsen; Leif Røge Lund; John Rømer
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.